A UK cost–effectiveness analysis of trifluridine/tipiracil for heavily pretreated metastatic gastroesophageal cancers

Figures & data

Figure 1. Model schematic.

OS: Overall survival; PD: Progressed disease; PF: Progression-free; PFS: Progression-free survival; t: Time.

Table 1. Key scenario analysis results.

Scenario	ICER (£)
Base-case analysis	37,907
Restrict time horizon to 5 years	39,034
Disable background mortality adjustment	37,906
OS model: independent log-logistic	39,173
OS model: independent lognormal	42,557
OS model: dependent generalized gamma	37,879
OS model: dependent log-logistic	33,247
PFS model: independent log-logistic	37,374
PFS model: independent lognormal	37,946
PFS model: independent Gompertz	37,553
TTD model: Gompertz	37,472
TTD model: Weibull	37,547
Utility values: Taken from NICE TA378	40,669
Utility values: Taken from NICE TA208	41,239
Exclude AE-related disutilities	37,259
Exclude QALYs lost due to AEs in subsequent treatment	37,926
Remove postprogression treatment costs	38,935

AE: Adverse event; ICER: Incremental cost–effectiveness ratio; NICE: National Institute for Health and Care Excellence; OS: Overall survival; PFS: Progression-free survival; QALY: Quality-adjusted life years; TTD: Time to treatment discontinuation.